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Abstract
ELISA is the main approach for the sensitive quantification of protein biomarkers in body flu-
ids and is currently employed in clinical laboratories for the measurement of clinical mark-
ers. As such, it also constitutes the main methodological approach for biomarker validation
and further qualification. For the latter, specific assay performance requirements have to be
met, as described in respective guidelines of regulatory agencies. Even though many clini-
cal ELISA assays in serum are regularly used, ELISA clinical applications in urine are signif-
icantly less. The scope of our study was to evaluate ELISA assay analytical performance in
urine for a series of potential biomarkers for bladder cancer, as a first step towards their
large scale clinical validation. Seven biomarkers (Secreted protein acidic and rich in cyste-
ine, Survivin, Slit homolog 2 protein, NRC-Interacting Factor 1, Histone 2B, Proteinase-3
and Profilin-1) previously described in the literature as having differential expression in blad-
der cancer were included in the study. A total of 11 commercially available ELISA tests for
these markers were tested by standard curve analysis, assay reproducibility, linearity and
spiking experiments. The results show disappointing performance with coefficients of varia-
tion>20% for the vast majority of the tests performed. Only 3 assays (for Secreted protein
acidic and rich in cysteine, Survivin and Slit homolog 2 protein) passed the accuracy thresh-
olds and were found suitable for further application in marker quantification. These results
collectively reflect the difficulties in developing urine-based ELISA assays of sufficient ana-
lytical performance for clinical application, presumably attributed to the urine matrix itself
and/or presence of markers in various isoforms.
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Introduction
To establish a protein as a disease biomarker, its accurate, sensitive and reproducible detection
and quantification in large numbers of samples representing the biomarker context of use is
necessary. The most common methods for protein biomarker validation are affinity-based
assays, such as enzyme-linked immunosorbent assays (ELISAs). ELISAs have high sensitivity
and reasonable specificity for the detection of protein amounts with concentration ranges of
ng/ml to pg/ml in serum. [1] Major limitations of this approach are the restricted number of
validated ELISAs for human proteins, the costly and lengthy development of novel assays, and
the limited multiplexing due to antibody (Ab) cross-reactivity. [2] These issues hinder the
rapid validation of putative biomarkers derived from high-throughput proteomic and genomic
studies. [3]
Research based on urine proteomics is crucial for the discovery of disease biomarkers espe-
cially of the renal and urogenital systems. In these latter cases, urine is apparently the most
appropriate body fluid that can actually be examined for detecting changes related to patho-
physiology as it is the filtrate of blood by the kidneys in direct contact with the bladder contain-
ing many soluble biomarker proteins. In addition, urine is easily available and can be collected
frequently and in a non-invasive way; consisting collectively an appropriate specimen for
proteomic biomarker research. [4,5]
Along these lines major efforts have been invested in recent years in biomarker investiga-
tions in urine for multiple diseases. [6,7] Bladder cancer (BC) is a major research area where
introduction of effective biomarkers is expected to be of major impact on patient management:
BC has the highest recurrence rate (approximately 30–70%) among all malignancies and
requires extensive patient monitoring for several years. The gold standard for BC initial diag-
nosis and follow up is cystoscopy (endoscopic examination of the bladder), which is invasive
and expensive. Urine cytology which is also used in the clinical setting lacks sensitivity for low
grade tumors and is characterized by inter-observer variability. [8] Thus, non-invasive
approaches with high sensitivity and specificity for early detection of primary tumors and
recurrences are needed. [9,10] An effective BC biomarker could allow reducing the number of
unnecessary cystoscopies especially among patients with low risk disease and as a result
improve the patients’ quality of life.
As a result of extensive research, several biomarker candidates have been identified follow-
ing analysis of the urine proteome of bladder cancer patients. [11–15] Nevertheless, despite
these efforts, no clinical implementation has been achieved yet, in most part due to lack of
appropriate validation studies establishing the biomarker context of use. [16,17] As a first step
towards the validation of previously discovered BC biomarker candidates, the objective of this
study was to evaluate the analytical performance of ELISA assays in urine. Biomarker candi-
dates include the: NRC-Interacting Factor 1 (NIF-1), Histone 2B (H2B), Profilin-1 (PFN-1),
Slit homolog 2 protein (SLIT-2), Proteinase-3 (PR3), and Secreted protein acidic and rich in
cysteine (SPARC) and Survivin. [12,18–20] In several cases (NIF-1, H2B, PFN-1) the associa-
tion of these proteins with BC at the tissue level has been proven [11,12] and initial verification
studies in urine have shown discriminatory potential of these marker for bladder cancer detec-
tion. [12,18,19] Survivin, has been described in multiple studies as a bladder cancer biomarker,
in most cases, based on RT-PCR measurements, [20] but also based on ELISA. [21] Neverthe-
less, no clear added value for the use of this marker has been demonstrated, in part due to sub-
optimal assays for its measurement. [20,22]
In this study, extensive analytical validation of commercially available ELISA assays for
these markers in urine was performed according to FDA guidelines, as a first step towards the
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validation of their clinical use. [23] This is particularly interesting since few studies on the ana-
lytical performance of ELISA assays in urine are available. [2]
Materials and Methods
Urine samples
Urine samples from benign cases and BC patients were collected at the Urology clinic of the
Laikon University Hospital, Athens, Greece in accordance to the local ethics regulations. The
Ethics committee of Laikon Hospital (protocol number ES618) specifically approved the
research for this study. In all cases, written consent forms were obtained.
The patients were selected according to the following criteria. Cases had bladder cancer pri-
mary tumors; controls suffered from benign urological conditions (hernia, etc).
Clinical data on the urine samples are presented in Table A in S7 File.
The samples were thawed, centrifuged at 2000 rpm for 10 min, and the supernatant was ali-
quoted to volumes ranging from 0.1 to 1.0 ml. Samples were stored at -20°C and aliquots were
thawed for ELISA assays and pH/protein/hematuria determination. Thawed aliquots were not
reused. The pH and hematuria of the urine samples was measured by using standard urine
analysis strips from EMAPOL and are presented in Table A in S7 File. The protein concentra-
tion of the urine samples was measured by the Bradford assay.
ELISA assays
The following commercially available ELISA kits were tested:
• SPARC: R&D Systems Inc., Minneapolis, MN 55413, USA (Catalogue no. DSP00)
• SLIT-2: Cloud Clone Corp., Houston, TX 77082, USA (Catalogue no. SEA672Hu)
• H2B: US Biological Life Sciences, Swampscott, Massachusetts 01907, USA (Catalogue no.
025705) and Cloud Clone Corp., Houston, TX 77082, USA (Catalogue no. SEA356Hu)
• Survivin: Enzo Life Sciences AG, Postfach CH-4415 Lausen/Switzerland (Catalogue no. ADI-
900-111), R&D Systems Inc., Minneapolis, MN 55413, USA (Catalogue no. DSV00)
• PFN-1: USCN LIFE, WUHAN EIAAB SCIENCE CO. LTD, Optics Valley, Wuhan, China
(Catalogue no. E2122h); US Biological Life Sciences, Swampscott, Massachussetts 01907,
USA (Catalogue no. 027613) and Cloud Clone Corp., Houston, TX 77082, USA (USCN Life
Science Inc., Catalogue no. SEC233Hu)
• NIF-1: Cusabio Biotech CO. LTD, Wuhan, Hubei Province 430206, P.R.China (Catalogue
no. CSB-EL026683HU) and USCN LIFE, WUHAN EIAAB SCIENCE CO. LTD, Optics Val-
ley, Wuhan, China (Catalogue no. E1019h)
• PR3: Cusabio Biotech CO. LTD, Wuhan, Hubei Province 430206, P.R.China (Catalogue no.
CSB- E13058h)
The type of plate reader used was ELx800 (BioTek Instruments).
Standard curve validation. Blanks and standards were assayed according to the manufac-
turer’s instructions in each case. All assays were performed in duplicate and in at least 2 differ-
ent days. The mean values of Absorbance vs. Concentration were plotted and a 4 Parameter
Logistic (4PL) nonlinear regression model) fit was applied (R2> 0.95 was acceptable).
Recovery. A negative urine sample was spiked with 3 different standards containing high,
medium and low concentration of the marker, in 4 replicates each time. The standard protein
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provided by each ELISA manufacturer was used for the spiking experiments. The % recovery
was calculated and the acceptable range was 80 to 120%.
Reproducibility. Three urine samples containing high, medium and low concentration of
the marker were selected and at least five technical replicates were assayed to calculate the coef-
ficient of variation (CV %) for intra-assay reproducibility. The acceptable range of CV was
0–20%.
The inter-assay reproducibility was evaluated only for the SLIT-2, Survivin, and SPARC
since these assays had satisfactory intra-assay reproducibility. Aliquots were used in order to
avoid freeze/thaw cycles.
Linearity. A urine sample with high marker concentration based on the present study and
a published report [11] was selected and serial dilutions (1:2 to 1:32) were performed. Each lin-
earity tests was performed in at least 4 replicates and the experimental versus theoretical con-
centrations were plotted. The acceptable range was a linear fit with R2>0.9 and a slope of 0.9–
1.0.
Limit of Detection (LOD) and Limit of Quantitation (LOQ). The LOD was provided by
each ELISA kit manufacturer. The LOQ was determined by interpolating the absorbance of the
lowest or highest standard on the standard curve.
Biomarker evaluation. The t-test was used to evaluate statistical differences between
groups (benign controls and tumor stages; tumor grades 1, 2, 3). The effect of hematuria on
ELISA results for SPARC, SLIT-2, and Survivin was assessed by the chi-square test.
Results
Most of the selected proteins had shown discriminatory power as BC biomarkers based on pre-
vious studies [11,12] However, no data in urine were available for SLIT-2 and SPARC; thereby
these two proteins were initially tested in a small number of BC urine samples and controls
(n = 167). In both cases, significantly higher levels of these proteins in BC samples compared to
controls were obtained underscoring the need for their further validation. (Figures A, B in S1
File)
As summarized in Table 1, a total of three ELISA kits targeting respectively SPARC, Survi-
vin and SLIT-2 successfully passed the analytical evaluation tests, whereas a total of 8 assays for
NIF-1, PFN-1, PR3 and H2B showed poor analytical performance (Table 1). SPARC (R&D
Systems, DSP00) and PR3 (Cusabio Biotech Co. LTD, E13058h) results are presented as exam-
ples of successful or poor analytical validation performance respectively (Figs 1–3, Tables 2
and 3), and detailed experimental data for each kit can be found in the supplementary informa-
tion section. For SPARC, the standards yielded reproducible results and a good fit to the 4
Parameter Logistic (4PL) nonlinear regression model (Fig 1A) Similarly, for PR3, the standards
yielded reproducible results and a good fit to the 4PL nonlinear regression model (Fig 1B). In
contrast to SPARC, the PR3 assay failed the rest of the analytical performance tests. For
SPARC, the % recovery for the medium and high standard was 118% and 108% respectively
passing the acceptance threshold (Table 2). Nevertheless, recovery was 136% for the low
SPARC levels, reflecting potential inaccuracies in the marker measurements at low concentra-
tions. (Table 2)
In contrast, for PR3, the % recovery for the low, medium, and high standards was 269%,
135%, and 126% respectively (Table 3) clearly exceeding the allowed acceptable recovery range.
When tested for reproducibility in measurement using high, medium and low biomarker
concentrations, as described in Materials and Methods section satisfactory CVs were obtained
for SPARC. For the low [SPARC] sample a CV of 4%, for the medium [SPARC] sample a CV
of 5% and for the high [SPARC] sample, a CV of 8% was obtained. (Fig 2A)
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For PR3, the CV% was above the acceptable 20% limit for the medium and high [PR3] sam-
ples (24% and 21% respectively). The low [PR3] sample had a satisfactory CV (7%). (Fig 2B)
When further tested for linearity the performance of the ELISA assay for SPARC was excel-
lent from dilution 1:2 up to 1:16 (R2 = 0.997 and a slope of 1.023). (Fig 3A) The respective val-
ues for PR3 were R2 = 0.965 which is acceptable, and a slope of 1.46 which is not acceptable.
(Fig 3B)
The majority of the remaining ELISA kits, even though successful for the standard curve
validation, failed either in reproducibility, or in recovery and linearity studies. For example, in
the spiking experiments of pure recombinant standards to negative urine samples, extremely
low (e.g. PFN-1 Elisa kit by US Biological, Figure G in S2 File) or high (e.g. NIF-1 Elisa kit by
CUSABIO, Figure I in S2 File) % recoveries were obtained. It is important to note that particu-
larly poor results were obtained in the linearity test for most of the assays (Figures A-G in S4
File).
The inter-assay reproducibility was evaluated for SLIT-2, Survivin, and SPARC since only
these assays had satisfactory intra-assay reproducibility. The CVs of the inter-assay reproduc-
ibility for these 3 ELISA kits are reported in Table A in S9 File. For SPARC the CVs of the
urine samples with low, medium and high concentration were 29%, 9% and 34% respectively.
For SLIT-2 the CVs of the urine samples with low, medium and high concentration were 43%,
34% and 11% respectively. For Survivin only the CV of a low concentration urine sample could
be assessed and was determined to be 41% (the available clinical urine samples were either
Table 1. Summary of analytical performance.
Protein Company Catalogue number Analytical performance
SPARC R&D Systems DSP00 Successful in all assays
SLIT-2 Cloud Clone Corp. SEA672Hu Failed in linearity assay
H2B US Biological Life Sciences 25705 Failed in recovery and reproducibility assays (linearity not possible)
Cloud Clone Corp. SEA356Hu Failed in recovery and reproducibility assays (linearity not possible)
SURVIVIN Enzo Life Sciences ADI-900-111 Failed in recovery, reproducibility and linearity assays
R&D Systems DSV00 Successful in all assays (linearity not possible)
PFN-1 USCN LIFE E2122h Failed in recovery, reproducibility and linearity assays
US Biological Life Sciences 27613 Failed in recovery, reproducibility and linearity assays
Cloud Clone Corp. SEC233Hu Failed in reproducibility and linearity assays
NIF-1 CUSABIO EL026683HU Failed in recovery, reproducibility and linearity assays
USCN LIFE E1019h Failed in recovery and linearity assays
PROTEINASE 3 CUSABIO E13058h Failed in recovery, reproducibility and linearity assays
doi:10.1371/journal.pone.0149471.t001
Fig 1. Standard curve validation of A) SPARC (R2 = 0.999) and B) PR3 (R2 = 0.996).
doi:10.1371/journal.pone.0149471.g001
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negative or had low Survivin concentration). Aliquots were used in order to avoid freeze/thaw
cycles.
The LOD and LOQ for each ELISA kit are listed in Table A in S10 File.
Hemoglobin released from erythrocyte lysis was measured by standard urine analysis strips
(EMAPOL) and its effect on the ELISA assay is reported. (Figure A in S5 File, Table A in S11
File, Table A in S12 File, Table A in S13 File). Hematuria affected significantly only the Survivin
ELISA assay as it is was determined by the chi-square statistical test.
The values of the SPARC and SLIT-2 ELISA kits and their dependence on tumor grade are
presented. (Figures A, B in S6 File) There is a gradual increase in the SLIT-2 values when
tumor grade increases but there is no statistically significant difference. In the case of SPARC
Grade 2 tumors have higher mean value compared to G1 and G3 without any statistically sig-
nificant difference. In both SPARC and SLIT-2 data the standard deviation is very high.
However given the limited number of samples analyzed, a more comprehensive multi-cen-
ter study is under way for evaluating the effect of tumor grade on SPARC and SLIT-2 ELISA
results.
Discussion
Recently, several urine-based bladder tumor markers have been evaluated and are implicated
in non-invasive clinical tests for BC detection. [24,25] The commercially available ELISA
assays include BTA, nuclear matrix protein 22, AccuDx, and UBC. Unfortunately these ELISA
urine biomarkers do not have better performance than cystoscopy and are significantly affected
by the presence of hematuria. There is no clearly demonstrated added value for using them in
initial diagnosis or patient monitoring. [17]
Fig 3. Linearity results of A) SPARC and B) PR3. For each biomarker a high concentration sample was
serially diluted and theoretical values were compared to the experimental.
doi:10.1371/journal.pone.0149471.g003
Fig 2. Reproducibility study results of A) SPARC and B) PR3. Three urine samples with low, medium and
high concentration were used.
doi:10.1371/journal.pone.0149471.g002
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Urine complexity hinders the development of methods for precise and reproducible protein
quantitation. [5] Urine contains more than 1,500 proteins, the majority of which are extracellu-
lar and membrane bound along with cells and cellular debris, inorganic ions (K+, Na+, Cl− and
Ca2+) and organic molecules such as creatinine, urea, and uric acid. All these substances can
hinder the efficient binding of a protein to its corresponding antibody used in an ELISA assay.
[12,26] Variability of urine matrix components such as electrolytes or pH can also have an
effect on antibody binding and therefore on the performance of the immunoassay. [27] In the
case of multiplex bead array assays, to compensate for the impact of matrix effects on biological
fluids, manufacturers have developed standard sample diluents for serum, plasma, cultured
cells. For urine, a diluent of phosphate buffered saline is recommended for use; however this
does not resolve the issue of variability of urine matrix components as the measurements
appear less stable compared to those in serum and plasma. [28] To our knowledge the only uri-
nary protein measured by ELISA in clinical laboratories is albumin. [4]
Nevertheless even in the case of albumin measurements multiple limitations have been
identified, mostly related to the presence of the protein in multiple isoforms. Many of these
forms are considered different to those in plasma. Currently, a reference standard material for
urine albumin is not available therefore serum albumin is used for calibration in urine assays.
In healthy individuals serum albumin, when filtered and excreted in urine, is composed of a
minor amount of intact protein (~4%) and a large amount of albumin fragments with MW in
the 1–15 kDa range (~96%). [29] However, it was shown that diabetic nephropathy gradually
increases the percentage of intact albumin in urine up to 35% in severe cases. [30] Conven-
tional ELISA assays can detect only certain forms of albumin and the antibodies used fail to
Table 3. Recovery study results of PR3. Negative urine samples were spiked with low, medium and
high concentration of standard.
Negative + 1.56 ng/ml PR3 (n = 4) Mean [PR3] (ng/ml) 2.10
Expected [PR3] (ng/ml) 0.78
% Recovery 269%
Negative + 6.25 ng/ml PR3 (n = 4) Mean [PR3] (ng/ml) 4.21
Expected [PR3] (ng/ml) 3.13
% Recovery 135%
Negative + 25 ng/ml PR3 (n = 4) Mean [PR3] (ng/ml) 15.74
Expected [PR3] (ng/ml) 12.50
% Recovery 126%
doi:10.1371/journal.pone.0149471.t003
Table 2. Recovery study results of SPARC. Negative urine samples were spiked with low, medium
and high concentration of standard.
Negative + 3.13 ng/ml SPARC (n = 8) Mean [SPARC] (ng/ml) 2.14
Expected [SPARC] (ng/ml) 1.57
% Recovery 136%
Negative + 12.5 ng/ml SPARC (n = 8) Mean [SPARC] (ng/ml) 7.4
Expected [SPARC] (ng/ml) 6.25
% Recovery 118%
Negative + 50 ng/ml SPARC (n = 8) Mean [SPARC] (ng/ml) 27
Expected [SPARC] (ng/ml) 25
% Recovery 108%
doi:10.1371/journal.pone.0149471.t002
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bind efficiently to many isoforms. [31] Despite these limitations Albumin ELISA is routinely
used in clinical laboratories mainly for diagnosis of kidney diseases. [32]
In light of these findings for one of the most abundant urinary proteins it is imperative to
evaluate the analytical performance of ELISA kits for the detection of candidate biomarkers in
urine. The FDA guidelines for Bioanalytical Method Validation were followed. [23] Unfortu-
nately, most ELISA assays used in this study did not pass these strict analytical criteria. Some
explanations for these disappointing results are presented along with a comparison to previous
urinary ELISA analytical performance studies.
Low recovery may be due to interference of antigen recognition caused by substances pres-
ent in urine (salts, organic molecules, etc.). High recovery may be due to non-specific binding
of proteins to the antibody immobilized on the ELISA plate. In a study by Taylor et al., in order
to determine the degree of matrix interference in protein measurement in urine, known con-
centrations of 5 proteins (IL-6, IL-8, MCP1, MP1a and TNFα) were spiked in urine samples of
4 kidney disease patients and assayed 4 times each. High variability was observed in protein
recovery in the urine samples even between assays indicating that matrix components differ
among urine samples and also highlighting their ability to variably interfere in accurate protein
measurement. [28]
Inter-assay reproducibility results were not acceptable (high CVs) for the three kits that
yielded satisfactory intra-assay reproducibility (SPARC from R&D Systems, SLIT-2 from
Cloud-Clone Corp. and Survivin from R&D Systems) (Table A in S9 File)
The failure of the linearity test is the major deficiency of most ELISA kits analyzed. A possi-
ble explanation of this deficiency is the fact that in urine proteins exist in multiple forms with
different affinities for the ELISA antibodies. As it was determined for Albumin, urinary pro-
teins are not present only as full length polypeptides but also as numerous low MW peptides
and exhibit unique post-translational modifications (PTMs) different from those in plasma.
[30,31,33] It is possible that some of these forms have higher Kd than the full length and do not
bind to the Ab upon dilution resulting in lower signal. (Figures D, G in S3 File) Moreover, the
linearity of the assay can be affected by the dilution of interfering salts and organic molecules.
As a result protein-Ab binding is enhanced and a higher signal is obtained (Figures A, F in S3
File). In the case of Survivin and SLIT-2, urine sample desalting was performed before ELISA
analysis. Unfortunately the desalting did not increase signal intensity and thus did not improve
assay performance (data not shown). For the two H2B Elisa kits and the Survivin Elisa kit from
R&D Systems the linearity tests could not be performed due to the unavailability of high con-
centration samples and the minimum detectable dose of each kit.
The poor performance of ELISA assays in urine presented in this study is not a unique
occurrence. A comprehensive evaluation of the analytical performance of ELISA assays for
Neutrophil gelatinase-associated lipocalin (NGAL) yielded poor results for recovery and linear-
ity. These findings indicated the presence of variability in urinary immunoassay performance
that needs to be taken into consideration in clinical sample analysis. [34]
The performance of SLIT-2 and SPARC in detecting BC recurrence and/or progression will
be assessed in the context of a large clinical study involving prospectively collected samples.
The effect of confounders, such as hematuria, on the ELISA assays and the diagnostic perfor-
mance of SPARC and SLIT-2 individually or in combination will be evaluated.
The shortcomings of the assays presented in this article reflect the difficulties on developing
robust ELISA in urine for clinical applications. An alternative to ELISA assays would be to
develop MRM (Multiple Reaction Monitoring) methods for determining biomarker concentra-
tion in urine. Beasley-Green et al., employed isotope dilution–mass spectrometry (ID–MS) and
multiple reaction monitoring (MRM) as a reference method to measure full-length albumin
and its fragments in urine. The assay showed outstanding specificity, reproducibility and
Analytical Performance of ELISA Assays in Urine
PLOS ONE | DOI:10.1371/journal.pone.0149471 February 18, 2016 8 / 12
sensitivity. Thus, MRM has the potential to be applied in the clinical setting for biomarker
measurements. [35]
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